The downregulation of PHGDH (Fig. 1G and Fig. 2F), a key enzyme often upregulated in other cancer types (Liu et al, 2020; Pacold et al, 2016; Zhang et al, 2023) and non-catalytically expressed lower in cancer dissemination and metastasis (Rossi et al., 2022), underscores PLK1’s unique ability to redirect metabolic flux in prostate cancer. Here, PHGDH is linked to prostate carcinoma.